US Broker Ratings

Inventiva S.A. (IVA) Stock Analysis: Unpacking a 150% Potential Upside with Strong Buy Ratings

Inventiva S.A. – American Depositary Shares (IVA) is garnering attention in the biotechnology sector, standing out with a remarkable 150.95% potential upside as indicated by analyst ratings. Headquartered in Daix,..

Collegium Pharmaceutical, Inc. (COLL) Stock Analysis: Exploring a Specialty Pharma with a 53.81% Upside Potential

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) stands as a compelling player in the healthcare sector, specifically within the drug manufacturers – specialty & generic industry. With a market capitalization of $1.11..

AxoGen, Inc. (AXGN) Stock Analysis: Navigating the 27.69% Upside Potential in the Healthcare Sector

In the competitive and rapidly evolving landscape of the healthcare sector, AxoGen, Inc. (NASDAQ: AXGN) is carving out a niche with its innovative solutions in peripheral nerve regeneration and repair...

Tilray Brands, Inc. (TLRY) Investor Outlook: Exploring the 68.71% Potential Upside

Tilray Brands, Inc. (NASDAQ: TLRY), a prominent player in the specialty and generic drug manufacturing industry, is making waves in the healthcare sector. Headquartered in Leamington, Canada, this lifestyle consumer..

CareDx, Inc. (CDNA) Stock Analysis: Unveiling a 50.76% Potential Upside in the Healthcare Sector

CareDx, Inc. (NASDAQ: CDNA), a key player in the diagnostics and research industry, stands out in the healthcare sector with a promising potential upside of 50.76%. Headquartered in Brisbane, California,..

Zevra Therapeutics, Inc. (ZVRA) Stock Analysis: Uncovering a 123% Upside Potential in Biotech

For investors eyeing growth in the biotechnology sector, Zevra Therapeutics, Inc. (NASDAQ: ZVRA) presents a compelling opportunity. With a current market capitalization of $573.39 million and a stock price of..

AnaptysBio, Inc. (ANAB) Stock Analysis: 18.10% Potential Upside with Strong Buy Ratings

AnaptysBio, Inc. (NASDAQ: ANAB), a clinical-stage biotechnology company focused on developing innovative immunology therapeutics, presents an intriguing opportunity for investors in the healthcare sector. With a market capitalization of $1.83..

Arcus Biosciences, Inc. (RCUS) Investor Outlook: Navigating a 49% Potential Upside in Biotech

Arcus Biosciences, Inc. (NASDAQ: RCUS), a rapidly evolving player in the biotechnology sector, continues to capture investor attention with its promising pipeline of cancer therapies. With a market cap of..

Eton Pharmaceuticals, Inc. (ETON) Stock Analysis: Anticipating a 62.99% Upside in the Rare Disease Sector

For investors with a keen eye on the healthcare sector, Eton Pharmaceuticals, Inc. (NASDAQ: ETON) presents a compelling opportunity. Specializing in the development and commercialization of treatments for rare diseases,..

Akebia Therapeutics, Inc. (AKBA) Stock Analysis: Exploring a Potential 214% Upside

Akebia Therapeutics, Inc. (NASDAQ: AKBA) is capturing investor attention with its promising potential upside of 214%. Specializing in the development and commercialization of therapeutics for kidney disease patients, Akebia operates..

Avadel Pharmaceuticals (AVDL) Stock Analysis: Navigating a 54.90% Revenue Growth in the Healthcare Sector

Avadel Pharmaceuticals plc (NASDAQ: AVDL), a biopharmaceutical company headquartered in Dublin, Ireland, is making waves in the healthcare sector, specifically within the niche of drug manufacturing for specialty and generic..

STAAR Surgical Company (STAA): Investor Outlook with Key Insights into Growth Potential and Market Position

STAAR Surgical Company (NASDAQ: STAA), a prominent player in the medical instruments and supplies industry, offers a compelling case for investors seeking opportunities in the healthcare sector. Specializing in the..

Akso Health Group (AHG): Investor Outlook on a Fast-Growing Chinese E-Commerce Platform

As Akso Health Group (NASDAQ: AHG) continues to make waves in the healthcare sector, individual investors are taking a closer look at this emerging player in the medical distribution industry...

Auna SA (AUNA) Stock Analysis: 44.58% Potential Upside Amidst Healthcare Expansion

Auna SA (AUNA), a key player in the medical care facilities sector, is currently capturing investor interest with its notable potential upside of 44.58%. Based in Luxembourg and operating across..

Claritev Corporation (CTEV) Stock Analysis: Unpacking the 179% Potential Upside

For individual investors eyeing the healthcare sector, Claritev Corporation (NASDAQ: CTEV) presents an intriguing opportunity. With its focus on data analytics and technology-enabled solutions for cost management and revenue integrity..

Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: A Biotech Powerhouse with 138.61% Potential Upside

Taysha Gene Therapies, Inc. (NASDAQ: TSHA) stands out in the biotechnology sector as a promising clinical-stage company, capturing investor attention with its compelling growth potential. Headquartered in Dallas, Texas, Taysha..

Nutex Health Inc. (NUTX) Investor Outlook: Strong Analyst Consensus and Potential Upside of 154.76%

For investors seeking opportunities in the healthcare sector, Nutex Health Inc. (NUTX) stands out with its compelling growth potential and strong analyst recommendations. Headquartered in Houston, Texas, Nutex Health operates..

Castle Biosciences, Inc. (CSTL) Stock Analysis: A Promising 91.55% Upside Potential Awaits Investors

Castle Biosciences, Inc. (NASDAQ: CSTL), headquartered in Friendswood, Texas, operates within the healthcare sector, focusing on the diagnostics and research industry. The company is renowned for its cutting-edge molecular diagnostics..

Zymeworks Inc. (ZYME) Stock Analysis: Exploring a 70% Upside Potential with Strong Buy Ratings

Zymeworks Inc. (NASDAQ: ZYME) has garnered significant attention in the biotechnology sector, drawing investor interest with its innovative approach to developing biotherapeutics for cancer, inflammation, and autoimmune diseases. With a..

Dianthus Therapeutics (DNTH) Stock Analysis: A Biotech Gem with a 55% Potential Upside

Dianthus Therapeutics, Inc. (NASDAQ: DNTH), a burgeoning name in the biotechnology landscape, is catching the eye of investors with its promising pipeline and significant growth potential. This clinical-stage company, headquartered..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds